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rates, remission rates and discontinuation rates due to adverse events were extracted 
and compared in a Bayesian meta-analysis. RESULTS: Three aripiprazole, 2 quetiap-
ine and ﬁve olanzapine trials were identiﬁed together reporting on 2979 patients. 
Aripiprazole augmentation showed numerically higher efﬁcacy rates compared to 
quetiapine and olanzapine. Response odds ratios (95%CI) compared to quetiapine 
and olanzapine were 1.34(0.82–2.06) and 1.52(1.00–2.19) respectively. Remission 
odds ratios compared to quetiapine and olanzapine were 1.3(0.78–2.07) and 
1.26(0.77–1.92) respectively. Aripiprazole augmentation showed numerically lower 
discontinuation rates due to adverse events compared to quetiapine and olanzapine 
(OR = 0.99(0.24–2.62) and 0.77(0.23–1.89)). CONCLUSIONS: Amongst augmenta-
tion treatments with atypical antipsychotics in MDD, aripiprazole shows a tendency 
towards higher efﬁcacy rates and lower discontinuation rates due to adverse events 
compared to quetiapine and olanzapine. More direct head-to-head trials are needed 
to assess the comparative efﬁcacy and safety of adjunctive antipsychotics in MDD.
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SCHIZOPHRENIA
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OBJECTIVES: This study aimed to determine distinct subgroups of schizophrenia 
patients based on their illness severity at baseline and characterize those who were 
most improved and those who worsened the most. METHODS: We used data from 
a large 3-year prospective, multi-site, observational non-interventional study of indi-
viduals treated for schizophrenia in the United States (US-SCAP). A hierarchical cluster 
analysis was performed to group the patients, using baseline clinical, functional, and 
resource utilization measures. Improvement of outcome was determined based on the 
distance from the deﬁned “worst baseline cluster” for each post-baseline measure. A 
trajectory analysis was used to group patients by improvement of outcome over the 
3-year study. RESULTS: Almost all participants (99% or 872/880) with 3-year data 
were found in a single outcomes trajectory, characterized by minimal changes from 
baseline cluster over the 3-year study period. Approximately one-fourth of individuals 
moved to a better outcome cluster while about 17% moved to a worse outcome cluster 
at each year. Only 4% of patients moved from the worst/next to worst cluster to the 
best/next to best cluster and 16.6% moved from the best/next to best cluster to the 
worst/next to worst cluster. Most improved patients were more likely than all other 
patients to have case management, to live in a supervised housing arrangement, and 
get assistance with securing social services and beneﬁts. CONCLUSIONS: The long-
term outcome trajectory for almost all schizophrenia patients in this 3-year naturalistic 
observational study was stable, devoid of change from the baseline cluster. Only a 
very small subgroup of patients experienced marked improvements, and they were 
more likely to be engaged in psychosocial rehabilitation. Although current ﬁndings 
may afﬁrm the value of psychosocial rehabilitation, results highlight the need to 
improve the relatively stagnant long-term illness trajectory of almost all chronically 
ill patients with schizophrenia.
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OBJECTIVES: Approved treatments for attention-deﬁcit/hyperactivity disorder 
(ADHD) in Canada comprise short-acting (SA) and long-acting (LA) stimulants and 
a LA nonstimulant medication. The objective of this study was to elucidate different 
drug treatment patterns to treat ADHD in Canada. METHODS: A retrospective 
prescription claims analysis of a random sample of 15,838 ADHD patients from the 
Quebec provincial health plan (RAMQ) database was conducted. Any patient with 
≥1 physician claim with an ADHD diagnosis and a claim for a treatment approved 
for ADHD from July 2004 to June 2009 was considered. RESULTS: The mean age 
of the study sample was 14.0 years (SD = 8); 72.6% of the sample were males. There 
were a total of 416,646 ADHD prescriptions during the 5-year study period. As a 
proportion of total prescriptions, use of SA medications declined from 72.83% in 
2004 to 26.38% in 2009, while use of stimulant and nonstimulant LA medications 
increased from 27.17% to 73.62% over the same period. Approximately half of the 
patients used both SA and LA medications either concomitantly or subsequently while 
approximately 30% used only SA and 19% used only LA. Among those patients who 
used both types of formulations, switching from SA to LA was the most frequent 
(27.9%) treatment pattern. A greater proportion of patients (6.4%) on LA methyl-
phenidates required augmentation with SA medications when compared with those 
on LA amphetamines (1.9%; p < 0.01). CONCLUSIONS: Results of this RAMQ 
database analysis illustrate that over time, patients shifted from the use of SA stimu-
lants to formulations that provide all-day coverage. Switching from SA to LA medica-
tions and augmentation of LA medications with SA medication are common treatment 
patterns observed in the management of ADHD with implications for patient care and 
the efﬁcient use of health care resources. Supported by funding from Shire Develop-
ment Inc.
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OBJECTIVES: The purpose of the review was to evaluate the efﬁcacy and safety of 
escitalopram compared with sertraline and venlafaxine in treatment of major depres-
sive disorder (MDD). METHODS: The analysis was performed in accordance with 
the rules of systematic review, based on Cochrane Collaboration guidelines and recom-
mendations of Health Technology Assessment Agency in Poland (AOTM). RESULTS: 
In this report there were two subanalyses conducted, evaluating the efﬁcacy and safety 
of escitalopram in comparison with sertraline and venlafaxine, both consisted of two 
multicenter, parallel-group, double-blinded, randomized clinical trials. In both com-
parisons efﬁcacy was evaluated, based on the mean changes in MADRS, HAM-D, 
CGI-S, CES-D, HAM-A and CGI-I grading scales, as well as safety analysis was 
performed. Period of eight weeks treatment with escitalopram and sertraline as well 
as venlafaxine resulted in decrease in number of MDD symptoms and quality of life 
improvement. Over 50% decrease in number of major depression symptoms in 
MADRS and HAM-D grading scales compared to baseline indicates high clinical 
relevance of obtained results, even though statistical signiﬁcance was not reached. 
Safety analysis showed similar safety proﬁles of all drugs taken into account. There 
were no statistical differences between populations in any of primary endpoints, except 
for withdrawals from the study due to adverse events in comparison of escitalopram 
vs venlafaxine favoring escitalopram. CONCLUSIONS: Escitalopram seems to be 
equally efﬁcient and safe drug as sertraline and venlafaxine in treatment of patients 
with MDD. The clinical-effectiveness analysis ascertained equivalence of efﬁcacy and 
similarity of safety proﬁle of escitalopram in comparison with sertraline and venla-
faxine in therapy of patients with MDD.
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OBJECTIVES: In pharmaceutical outcomes research using health care claims data-
bases, periods during which patients are hospitalized have constituted “black holes”, 
as these databases do not contain any information on pharmacotherapy received in 
hospital. While admission-level databases provide such information, they lack infor-
mation on pharmacotherapy received outside of hospital. Recently, it has become 
possible to link these two types of databases. In this study, we explored their potential 
value to outcomes research, focusing attention on second-generation antipsychotic 
(SGA) treatment before, during, and after hospitalization for schizophrenia. 
METHODS: Using a linked inpatient/outpatient database, we identiﬁed all adults with 
≥1 admissions for schizophrenia between January 1, 2001 and September 30, 2008. 
Focusing on each patient’s ﬁrst admission, we compiled all health care claims during 
the 6-month periods preceding and following hospitalization. As our interest was in 
the use of SGAs, our scope was limited to patients with evidence of receipt of oral 
ziprasidone, aripiprazole, or quetiapine (“study agents”) immediately preceding hos-
pital discharge. We then examined receipt of these agents during the 6-month periods 
preceding hospitalization and following hospital discharge based on outpatient phar-
macy claims; receipt of study agents in hospital was examined using admission-level 
data. Adherence with study agents following hospital discharge was assessed using 
proportion of days covered (PDC); patients were deemed nonadherent if PDC fell 
below 80%. RESULTS: A total of 43 patients were identiﬁed who met all study entry 
criteria. Twenty-four patients (56%) had evidence of receipt of a study agent in the 
period preceding hospitalization. While all patients had evidence of receipt of study 
agents following hospital discharge, only 12% were adherent at 6 months. CONCLU-
SIONS: Linked inpatient/outpatient databases are a promising avenue for future 
pharmaceutical outcomes research, as they may greatly expand understanding of the 
complete chronology of pharmacotherapy–and associated outcomes–for many disease 
conditions.
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OBJECTIVES: To examine prevalence and predictors of anticholinergic medication 
use in elderly nursing home residents with dementia. METHODS: The study evaluated 
anticholinergic medication use in elderly (>= 65 years) nursing home residents using 
the 2004 National Nursing Home Survey (NNHS). Anticholinergic Drug Scale was 
used to classify medications as Level 1, Level 2 or Level 3 in order of their increasing 
anticholinergic activity. Descriptive weighted analysis was used to determine the 
prevalence of anticholinergic medication use in elderly dementia patients. Multinomial 
logistic regression within the conceptual framework of Andersen Behavioral Model 
(ABM) was used to examine the predictors associated with each level of anticholinergic 
medication use as well as concurrent use of anticholinergic medications belonging to 
two or more levels. RESULTS: According to the NNHS, 0.51 million (95% CI-0.49–
0.53) or 73.62% (72.23–75.00) of the elderly patients with dementia used anticho-
